Persistent Atrial Fibrillation is Associated with Reduced Risk of Torsades De Pointes in Patients with Drug-induced Long QT Syndrome
Overview
Affiliations
Objectives: The goal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associated long QT syndrome (LQTS).
Background: Drug-induced LQTS includes individuals developing marked prolongation of ventricular repolarization on exposure to an offending drug. Under these conditions, TdP develops in some but not all patients.
Methods: This was a case-control study of 123 adults with drug-associated LQTS. Patients were divided into LQTS only (LQTS; n = 40, QT >500 ms on drug) and LQTS + TdP (TdP; n = 83).
Results: Baseline QT intervals were similar in the 2 groups (381 +/- 38 ms [LQTS] vs. 388 +/- 43 ms [TdP]). Clinical variables associated with risk of TdP included hypokalemia and female gender; by contrast, persistent atrial fibrillation (AF) at the time of drug discontinuation for QT prolongation was protective despite similar heart rates in AF and sinus rhythm (n = 20, 71 +/- 13 beats/min vs. 69 +/- 13 beats/min). Electrocardiographic variables that significantly increased the risk for TdP included absolute and rate-corrected QT intervals (QTc) on drug therapy, the magnitude of QT and QTc interval prolongation, and the change in T(peak) to T(end) (DeltaT(p)-T(e)), a relatively new index of transmural dispersion of repolarization and potential arrhythmogenicity. Multivariable logistic regression analysis revealed that only gender was predictive for TdP, whereas persistent AF at the time of drug discontinuation for QT prolongation (odds ratio 0.14, 95% confidence interval 0.03 to 0.63, p = 0.01) was negatively associated with the arrhythmia.
Conclusions: This study strongly suggests that despite ongoing rate irregularity, AF reduces the likelihood of developing TdP after the administration of drugs that prolong cardiac repolarization.
Sacubitril Does Not Exert Proarrhythmic Effects in Combination with Different Antiarrhythmic Drugs.
Ellermann C, Mengel C, Wolfes J, Wegner F, Rath B, Kobe J Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006043 PMC: 11859141. DOI: 10.3390/ph18020230.
Ly O, Brown G, Han Y, Darbar D, Khetani S Exp Biol Med (Maywood). 2021; 246(16):1816-1828.
PMID: 33899540 PMC: 8381703. DOI: 10.1177/15353702211009146.
Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation.
Lenhoff H, Darpo B, Page A, Couderc J, Tornvall P, Frick M Ann Noninvasive Electrocardiol. 2021; 26(4):e12834.
PMID: 33629473 PMC: 8293609. DOI: 10.1111/anec.12834.
Use of a Smartwatch for Assessment of the QT Interval in Outpatients with Coronavirus Disease 2019.
Chinitz J, Goyal R, Morales D, Harding M, Selim S, Epstein L J Innov Card Rhythm Manag. 2020; 11(9):4219-4222.
PMID: 32983590 PMC: 7510469. DOI: 10.19102/icrm.2020.1100904.
Matsunaga-Lee Y, Egami Y, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumoto K J Cardiol Cases. 2020; 21(6):209-212.
PMID: 32547654 PMC: 7283284. DOI: 10.1016/j.jccase.2020.02.007.